ENGOT-ov65/KEYNOTE-B96: Phase 3, randomized, double-blind study of pembrolizumab versus placebo plus paclitaxel with optional bevacizumab for platinum-resistant recurrent ovarian cancer
Tarih
2022Yazar
Colombo, Nicoletta
Coleman, Robert L.
Wu, Xiaohua
Kose, Fatih
Wenham, Robert Michael
Sebastianelli, Alexandra
Hasegawa, Kosei
Zsiros, Emese
Rouge, Thibault De la Motte
Bidzinski, Mariusz
McNeish, Iain A.
Sehouli, Jalid
Korach, Jacob
Debruyne, Philip R.
Kim, Jae-Weon
De Melo, Andrea C.
Peng, Xuan
Bogusz, Agata M.
Yamada, Karin Sayuri
Monk, Bradley J.